Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XS411CN Cell Injection in Multiple System Atrophy Parkinsonian Variant (MSA-P)
NCT07617012Phase 1Not yet recruiting
- Start
- Jun 2026
- Primary completion
- Aug 2026
01
Overview
Phase 1, open-label, single-arm trial of XS411CN in multiple system atrophy (MSA). Primary endpoint: Safety and tolerability of stereotactic intracerebral transplantation of XS411CN cells at 28 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
XS411CN
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT07617012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07617012.